Articles from Oncolytics Biotech Inc.

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special meeting of shareholders (the “Special Meeting”), as described in its news release dated October 20, 2025, which was to be held on December 15, 2025. The Special Meeting is being rescheduled due to delays at the Securities and Exchange Commission caused by the recent shutdown of the federal government in the United States. Once rescheduled, the Special Meeting will be held in order to vote on, among other things, a series of transactions that would change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (the “Domestication”).

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration (“FDA”) regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).